Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease

Patent metadata

Field	Value
Publication number	US-9505739-B2
Application number	US-201414518825-A
Country	US
Kind code	B2
Filing date	Oct 20, 2014
Priority date	Feb 20, 2009
Publication date	Nov 29, 2016
Grant date	Nov 29, 2016

Abstract

The present invention is directed to spiropyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

First claim

What is claimed is:

1. A compound of the formula (IV):

or a pharmaceutically acceptable salt thereof, wherein:
R 2 is selected from
(1) hydrogen
(2) C 1-6 alkyl,
(3) C 2-6 alkenyl,
(4) —C 3-9 cycloalkyl,
(5) —C 6-10 aryl,
(6) heteroaryl group having from 5 to 12 ring atoms, wherein at least one ring atom is a heteroatom selected from the group consisting of nitrogen, sulfur or oxygen,
(7) a heterocyclic group having 4 to 8 ring atoms, wherein at least one ring atom is a heteroatom selected from the group consisting of nitrogen, sulfur or oxygen,
wherein said alkyl, alkenyl, aryl, cycloalkyl, heterocyclic or heteroaryl R 2 moiety is optionally substituted with one or more
(a) halo,
(b) —OH,
(c) —CN,
(d) —C 1-6 alkyl,
(e) —C 3-8 cycloalkyl,
(f) —O—C 1-6 alkyl,
(g) —O—CH 2 —C 6-10 aryl,
(h) —C 6-10 aryl,
(i) heteroaryl group having from 5 to 12 ring atoms, wherein at least one ring atom is a heteroatom selected from the group consisting of nitrogen, sulfur or oxygen,
(j) oxo,
(k) a heterocyclic group having 4 to 8 ring atoms, wherein at least one ring atom is a heteroatom selected from the group consisting of nitrogen, sulfur or oxygen,
(l) —O—CH 2 —C 3-8 cycloalkyl,
(m) —C(═O)—C 1-6 alkyl, or
(n) —NR 5A R 5B ;

R 3 and R 4 are each independently selected from:
(1) hydrogen,
(2) OH,
(3) —C 1-6 alkyl,
(4) —CN,
(5) —C 6-10 aryl, or
(6) heteroaryl group having from 5 to 12 ring atoms, wherein at least one ring atom is a heteroatom selected from the group consisting of nitrogen, sulfur or oxygen,
wherein said alkyl, aryl or heteroaryl R 2 or R 3 moiety is optionally substituted with one or more
(a) halo,
(b) —C 1-6 alkyl, wherein said alkyl is optionally substituted with one or more halogen, and
(c) —O—C 1-6 alkyl; and

R 10 and R 11 are each independently selected from:
(1) hydrogen,
(2) —C 1-6 alkyl,
(3) hydroxyl,
(4) —(CH 2 ) m C 6-10 aryl
(5) —C 2-6 alkenyl,
(6) —O—C 1-6 alkyl,
(7) halogen,
(8) —SO 2— C 1-6 alkyl,
(9) —NR 5A R 5B ,
(10) —C 3-8 cycloalkyl,
(11) —C(═O)—(O) m —C 1-6 alkyl,
(12) —C(═O)—(O) m —C 6-10 aryl,
(13) —C(═O)—NH—C 1-6 alkyl, and
(14) —S(═O) 2 —C 6-10 aryl,
wherein said alkyl, cycloalkyl, alkenyl or aryl moiety is optionally substituted with one or more
(a) halo,
(b) hydroxyl,
(c) —C 1-6 alkyl,
(d) —NR 5A R 5B ,
(e) —O—C 1-6 alkyl, and
(f) —C 6-10 aryl,
wherein said wherein said alky or aryl is optionally substituted with one or more halo;

R 5A and R 5B are independently selected from the group consisting of
(1) hydrogen,
(2) —C 1-6 alkyl,
(3) —C(═O)—(O) m —C 1-6 alkyl,
(4) —C(═O)—(O) m —C 6-10 aryl,
(5) —SO 2 —C 3-8 cycloalkyl,
(6) —SO 2 —C 1-6 alkyl,
(4) —C(═O)—NR 6A R 6B , wherein R 6A and R 6B are selected from the group consisting of
wherein the alkyl, cycloalkyl or aryl moiety is optionally substituted with one or more
(a) halogen,
(b) hydroxyl,
(c) —O—C 1-6 alkyl, or
(d) —C(═O)—(O) m —C 1-6 alkyl,

or R 6A and R 6B are linked together with the nitrogen to which they are attached to form a 4-6 membered carbocyclic ring, wherein one or two of the ring carbon atoms is optionally replaced by a nitrogen, oxygen or sulfur, and the ring is optionally substituted with one or more
(a) halogen,
(b) hydroxyl,
(c) C 1-6 alkyl,
(d) —O—C 1-6 alkyl,
(e) —C(═O)—(O) m —C 1-6 alkyl, or
(f) —SO 2 —C 1-6 alkyl; and

m is 0 or 1.

2. The compound of claim 1 , wherein R 2 is selected from
(1) hydrogen
(2) C 1-6 alkyl,
(3) C 3-6 cycloalkyl, or
(4) phenyl,
wherein said alkyl, cycloalkyl or phenyl R 1 moiety is optionally substituted with one or more
(a) halo,
(b) —OH,
(c) —CN,
(d) —C 1-6 alkyl
(e) —C 3-6 cycloalkyl, and
(f) —O—C 1-6 alkyl.

3. The compound of claim 1 , wherein R 2 is selected from hydrogen, phenyl (optionally substituted with halogen), and cyclohexyl.

4. The compound of claim 2 , wherein:
R 3 is hydrogen; and
R 4 is selected from:
(1) hydrogen,
(2) aryl (for example, phenyl), or
(3) heteroaryl,
wherein said aryl or heteroaryl R 3 moiety is optionally substituted with one or more groups independently selected from:
(a) halo,
(b) —C 1-6 alkyl, wherein said alkyl is optionally substituted with one or more halogen, and
(c) —O—C 1-6 alkyl.

5. The compound of claim 3 , wherein R 3 is hydrogen; and R 4 is hydrogen or unsubstituted phenyl.

6. The compound of claim 2 , wherein R 3 and R 4 are linked together to form cyclic group of 4-10 ring carbon atoms, wherein one or two of the ring carbon atoms is replaced by an oxygen, nitrogen or sulfur.

7. A compound, or a pharmaceutically acceptable salt thereof, said compound or pharmaceutically acceptable salt thereof selected from the group consisting of:

8. A compound, or a pharmaceutically acceptable salt thereof, said compound or pharmaceutically acceptable salt thereof selected from the group consisting of:

9. A pharmaceutical composition, comprising a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

10. A pharmaceutical composition, comprising a therapeutically effective amount of a compound of claim 7 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

11. A pharmaceutical composition, comprising a therapeutically effective amount of a compound of claim 8 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Assignees

• Merck Sharp & Dohme

Inventors

• Stachel Shawn J
• Coburn Craig A
• Steele Thomas G
• Wu Hao

Classifications

• C07D495/10

  Spiro-condensed systems · CPC title

• C07D209/96

  Spiro-condensed ring systems · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• C07D491/107

  with only one oxygen atom as ring hetero atom in the oxygen-containing ring · CPC title

• C07D513/20

  Spiro-condensed systems · CPC title